about
Antiobesity pharmacotherapy: new drugs and emerging targetsThe future role of gut hormones in the treatment of obesityCurrent trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.Regulation of appetite to treat obesity.New advances in models and strategies for developing anti-obesity drugs.Obesity treatment: novel peripheral targets.Obesity pharmacotherapy: what is next?Position and length of fatty acids strongly affect receptor selectivity pattern of human pancreatic polypeptide analogues.Gut-Brain Endocrine Axes in Weight Regulation and Obesity PharmacotherapyPharmacokinetics, adverse effects and tolerability of a novel analogue of human pancreatic polypeptide, PP 1420.A novel peptide nanomedicine for treatment of pancreatogenic diabetes.Neuropeptide Y inhibits the trigeminovascular pathway through NPY Y1 receptor: implications for migraine.Human pancreatic polypeptide in a phospholipid-based micellar formulation.The 'endocrine' enzyme secretion from the pancreas.The physiological implications of secretin.Pancreatic polypeptide.High molecular weight PEGylation of human pancreatic polypeptide at position 22 improves stability and reduces food intake in mice.Degradation Paradigm of the Gut Hormone, Pancreatic Polypeptide, by Hepatic and Renal Peptidases.The relative values of serum immuno-reactive trypsin concentration and total amylase activity in the diagnosis of mumps, chronic renal failure, and pancreatic disease.
P2860
Q30354242-06ADA3D1-3EC0-40B8-8C72-D7E128A55987Q30357431-DDCB0966-C781-4BAE-BFA5-23E0382F4D6FQ30399390-E2241DE8-3E41-428D-8977-2A0144C349E0Q30403705-02EB61B6-3094-434E-9EA6-D2D3DE9363A5Q30429816-BB2737B3-DDAB-4FB5-8B22-572714B64721Q33607971-EF599DAC-E9FE-4F4D-8F65-4628BD81AFA3Q33827988-57AFDB44-CCB1-4197-86DE-B3DB82F62D39Q33919544-C3411D71-382E-4352-BD40-33A4EADFFF29Q35667150-43A67FEC-10B4-4729-A599-10C91ECE033CQ35718588-AD52D515-94EE-456A-976B-0CC11A5A4A14Q36875741-9E34D580-54A0-4955-B7C6-A21F9CC20D32Q37104106-1A7AD5A7-B4FB-499D-B54B-D11B0FB1FF7BQ39383638-B990C66A-E6A9-4EF9-8589-3D1EF1901920Q39742265-ECAD9F04-A42E-4B47-9115-FFD688684846Q40295716-9C1EABD8-B7BF-49C1-BE41-929B5A00029DQ41903841-94D23D4C-FFD7-483B-A618-B24C1C176E79Q42709946-777E7CC9-1853-41A3-8610-EF284C049FF2Q44945151-99ECEC56-CBDC-4CA6-A9C8-24A85847DA63Q51660889-8F5CEC18-640F-48C1-9DFE-A6D85E0881A8
P2860
description
1978 nî lūn-bûn
@nan
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
1978年论文
@zh
1978年论文
@zh-cn
name
Pharmacokinetics of pancreatic polypeptide in man
@en
Pharmacokinetics of pancreatic polypeptide in man
@nl
type
label
Pharmacokinetics of pancreatic polypeptide in man
@en
Pharmacokinetics of pancreatic polypeptide in man
@nl
prefLabel
Pharmacokinetics of pancreatic polypeptide in man
@en
Pharmacokinetics of pancreatic polypeptide in man
@nl
P2093
P2860
P356
P1433
P1476
Pharmacokinetics of pancreatic polypeptide in man
@en
P2093
Besterman HS
Greenberg GR
P2860
P304
P356
10.1136/GUT.19.10.907
P407
P577
1978-10-01T00:00:00Z